Leap Therapeutics, Inc. (LPTX) Analysts See $-0.48 EPS

July 14, 2018 - By Megan Stone

Analysts expect Leap Therapeutics, Inc. (NASDAQ:LPTX) to report $-0.48 EPS on August, 10.They anticipate $0.26 EPS change or 35.14 % from last quarter’s $-0.74 EPS. After having $-0.46 EPS previously, Leap Therapeutics, Inc.’s analysts see 4.35 % EPS growth. The stock decreased 2.40% or $0.21 during the last trading session, reaching $8.55. About 19,710 shares traded. Leap Therapeutics, Inc. (NASDAQ:LPTX) has risen 22.88% since July 14, 2017 and is uptrending. It has outperformed by 10.31% the S&P500.

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapeutics in cancer biology. The company has market cap of $125.69 million. The Company’s clinical stage programs include DKN-01, a monoclonal antibody targeting Dickkopf-related protein 1, which is in Phase I/II clinical trial in patients with esophagogastric and biliary tract cancers, as well as in Phase I clinical trial in patients with non-small cell lung cancer; and TRX518, a monoclonal antibody that is in Phase I clinical trial targeting the glucocorticoid-induced tumor necrosis factor-related receptor in patients with solid tumors. It currently has negative earnings. Leap Therapeutics, Inc. has a clinical trial collaboration agreement with Merck & Co., Inc. to investigate Leap??s DKK1 antagonist, DKN-01, in combination with Merck??s anti-PD-1 therapy, KEYTRUDA, in patients with relapsed or refractory advanced esophagogastric cancers.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.